Dr. Goldberg Discusses Resistance to EGFR TKI Therapy in NSCLC
March 8th 2018Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses testing for and treating resistance to EGFR tyrosine kinase inhibitor (TKI) therapy in non–small cell lung cancer.